Serious setback in the long-term treatment of HIV infectionOctober 10, 2002Structured therapeutic interruptions (STI), long hailed as a way of reducing the side effects of long-term AIDS treatment, has been shown to be ineffective, according to a collaborative study between Swiss and British researchers. Professor Rodney Phillips and colleagues at Oxford University's Peter Medawar Building for Pathogen Research and the Zoology Department collaborated with a Swiss Consortium based in Geneva to study the effect of manipulation of the treatment given to Swiss and Spanish nationals infected with HIV. The researchers sought evidence for benefit to patients when potent antiretroviral therapy (ART), the standard treatment of people infected with HIV, is interrupted in a controlled way in order to boost the patient's natural immunity to the virus, and perhaps minimise drug side effects. The idea arose from case studies and small trials carried out in Europe and the US. In this definitive trial, called the `Swiss Spanish Intermittent Therapy Trial`, over 130 patients with chronic HIV infection from both countries were enrolled. The large size of this trial gave it analytic power of a high order. It revealed very clearly that the orderly starting and stopping of drugs did not, on balance, produce a clinically useful or lasting benefit. This finding, which comes only one year after the Peter Medawar Building for Pathogen Research was established, has important implications for the use of these drugs worldwide. In developing countries a particularly attractive extra benefit would have been savings in the costs of medicine but those hopes are dashed by this trial. However, there may still be some potential for this sort of manipulation to work in the earliest, acute phase of the disease, as Phillips` group in Oxford and his colleagues in Boston have shown. The study was partly funded by the Wellcome Trust | |||||||||||||||||||||
|
Related HIV Current Events and HIV News Articles Disease diagnosis in just 15 minutes Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit. Urbanization in Africa at dawn of 20th century marked outbreak of HIV New research indicates that the most pervasive global strain of HIV began spreading among humans between 1884 and 1924, suggesting that growing urbanization in colonial Africa set the stage for the HIV/AIDS pandemic. New findings indicate HIV/AIDS pandemic began around 1900, earlier than previously thought New research indicates that the most pervasive global strain of HIV began spreading among humans between 1884 and 1924, not during the 1930s, as previously reported. Will patients stick to physical therapy? Questionnaire can help doctors predict Patients' responses to a simple questionnaire can reliably predict whether they will adhere to physical therapy after spine surgery, Johns Hopkins researchers suggest in a new study. MU scientists 'see' how HIV matures into an infection After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature. HIV drug maraviroc effective for drug-resistant patients As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Scientists unmask key HIV protein, open door for more powerful AIDS drugs University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response. New way to make malaria medicine also first step in finding new antibiotics University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive. Existing anti-obesity drugs may be effective against flu, hepatitis and HIV Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology. New UNC laboratory to help track and control tropical diseases The University of North Carolina at Chapel Hill School of Public Health has established a new Gillings Innovation Lab to track and map tropical infectious diseases such as malaria, using state-of-the-art molecular and demographic methods. More HIV Current Events and HIV News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||